Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status-Reference-Cited by-同舟云学术

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

Published:2014-09-12 Issue:12 Volume:28 Page:2292-2299
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Schmidt M,Rinke J,Schäfer V,Schnittger S,Kohlmann A,Obstfelder E,Kunert C,Ziermann J,Winkelmann N,Eigendorff E,Haferlach T,Haferlach C,Hochhaus A,Ernst T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014272.pdf

Reference46 articles.

1. Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

2. Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

3. Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197–2203.

4. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767–771.

5. Fabarius A, Giehl M, Rebacz B, Krämer A, Frank O, Haferlach C et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 2008; 93: 1145–1154.

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population;Indian Journal of Hematology and Blood Transfusion;2024-06-21

2. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes;Blood Advances;2024-05-17

3. The dark side of stemness – the role of hematopoietic stem cells in development of blood malignancies;Frontiers in Oncology;2024-02-19

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. Somatic mutations in myeloid transcription factors and in activated signaling genes predict the risk of treatment failure and progression to advanced phase in chronic myeloid leukemia;2023-09-22